Dexcom (NSDQ:DXCM) said yesterday that it plans to pay $250 million upfront in stock to Verily in an amended collaboration and licensing deal.
The two companies are working to develop a second-generation continuous glucose monitoring system. The updated deal also notes that the companies could collaborate on additional products and software.
Get the full story at our sister site, Drug Delivery Business News.